Update
$Moleculin Biotech (MBRX.US)$ New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML
2 MINUTES AGO, 8:15 AM EST
VIA PR NEWSWIRE
Preclinical data accepted for online publication at ASH Annual Meeting reveal significant activity of Annamycin in Venetoclax resistant AML model
New preliminary clinical results show Annamycin plus Ara-C achieved 60% CR/CRi in subjects who were relapsed from or refractory to Venetoclax regimens; more than 4 times greater than published historical rates
Annamycin demonstrates an even greater potential than previously reported to address a significant AML patient population for which treatment options are extremely limited
New data from MB-106 trial show median overall survival of 11.6 months in subjects receiving AnnAraC as 2nd line therapy
2 MINUTES AGO, 8:15 AM EST
VIA PR NEWSWIRE
Preclinical data accepted for online publication at ASH Annual Meeting reveal significant activity of Annamycin in Venetoclax resistant AML model
New preliminary clinical results show Annamycin plus Ara-C achieved 60% CR/CRi in subjects who were relapsed from or refractory to Venetoclax regimens; more than 4 times greater than published historical rates
Annamycin demonstrates an even greater potential than previously reported to address a significant AML patient population for which treatment options are extremely limited
New data from MB-106 trial show median overall survival of 11.6 months in subjects receiving AnnAraC as 2nd line therapy
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
